DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phase
29 févr. 2024 05h42 HE
|
Mithra Pharmaceuticals
DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phase Mithra on-track for completion of Phase 3 study for DONESTA® to treat...
Mithra sells shares in Mayne Pharma
15 févr. 2024 12h23 HE
|
Mithra Pharmaceuticals
Mithra sells shares in Mayne Pharma Mithra sold all 4,221,815 shares it held in Mayne Pharma for EUR ~12.8 millionAs the Mayne Pharma shares were pledged to the secured lenders of Mithra,...
Mithra to receive EUR 2.5 million milestone payment from Fuji Pharma under ESTELLE® licensing agreement
23 oct. 2023 01h00 HE
|
Mithra Pharmaceuticals
Mithra to receive EUR 2.5 million milestone payment from Fuji Pharma under ESTELLE® licensing agreement Relates to the submission of a marketing approval application in JapanMarks strong...
Letter to Shareholders and Corporate Update
11 sept. 2023 01h30 HE
|
Mithra Pharmaceuticals
Letter to Shareholders and Corporate Update Liege, Belgium, 11 September 2023 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, (the “Company” or “Mithra”),...
Mithra completes EUR 20 million private placement in equity. Update of total number of voting rights (denominator)
28 août 2023 11h45 HE
|
Mithra Pharmaceuticals
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED...
Mithra and Searchlight Pharma Announce Donesta® Licensing Agreement for Canada
31 juil. 2023 01h30 HE
|
Mithra Pharmaceuticals
Mithra and Searchlight Pharma Announce Donesta® Licensing Agreement for Canada Mithra to receive up to €17.05 million in licensing fees and regulatory and sales milestones, along with tiered...
Mithra and Searchlight Pharma Announce Donesta® Licensing Agreement for Canada
31 juil. 2023 01h30 HE
|
Mithra Pharmaceuticals
Mithra and Searchlight Pharma Announce Donesta® Licensing Agreement for Canada Mithra to receive up to €17.05 million in licensing fees and regulatory and sales milestones, along with tiered...
Notice of Adjustment of the Conversion Price of Mithra's EUR 125,000,000 Senior Unsecured Convertible Bonds due 2025
17 juil. 2023 11h45 HE
|
Mithra Pharmaceuticals
Notice of Adjustment of the Conversion Price of Mithra's EUR 125,000,000 Senior Unsecured Convertible Bonds due 2025 (ISIN: BE6325746855) Liege, Belgium, 17 July 2023 – 17:45 CEST – Mithra...
Notice of Adjustment of the Conversion Price of Mithra's EUR 125,000,000 Senior Unsecured Convertible Bonds due 2025 (ISIN: BE6325746855)
04 juil. 2023 11h45 HE
|
Mithra Pharmaceuticals
Notice of Adjustment of the Conversion Price of Mithra's EUR 125,000,000 Senior Unsecured Convertible Bonds due 2025 (ISIN: BE6325746855) Liege, Belgium, 4 July 2023 – [17:45 CEST] – Mithra...
Mithra Appoints Experienced Life Sciences Executive Christian Homsy* as Chairman
29 mai 2023 01h30 HE
|
Mithra Pharmaceuticals
Inge Beernaert appointed President of the Compensation and Nomination CommitteeJacques Galloy appointed President of the Audit Committee Liege, Belgium, 29 May 2023 – 7:30 CEST – Mithra (Euronext...